Aliskiren/amlodipine/hydrochlorothiazide
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Amlodipine | Calcium channel blocker |
| Hydrochlorothiazide | Diuretic |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| (verify) | |
The drug combination aliskiren/amlodipine/hydrochlorothiazide (INNs, trade name Amturnide) is an antihypertensive approved by the U.S. Food and Drug Administration (FDA) on December 21, 2010.[1]
References
External links
| ACE inhibitors ("-pril") | |
|---|---|
| AIIRAs ("-sartan") | |
| Renin inhibitors ("-kiren") | |
| Dual ACE/NEP inhibitors |
|
| Neprilysin inhibitors | |
| |
| Sulfonamides (and etacrynic acid) |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Potassium-sparing (at CD) |
| ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD) | |||||||||
| Other | |||||||||
| |||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.